FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

3...,

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STAAB THOMAS R II					<u>B</u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]							[(Ch	eck all applic Directo Officer	tionship of Reporting Pers all applicable) Director Officer (give title below)		rson(s) to Issuer 10% Owner Other (specify below)	
(Last) 4505 EM SUITE 2	(First) (Middle) PEROR BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 01/01/2015								,	Senior Vice President and CFO				
(Street) DURHA	M N	NC 27703				4. If Amendment, Date of Original Filed (Month/Day/Year)							Line) X Form fi Form fi	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(S	itate)	(Zip)	- D		0.		A		D:-		: D	4: . : . !!					
Date			nsactio	action 2A. Deemed Execution IDay/Year) if any		A. Deemed recution Date,		3. Transaction Code (Instr.		es Acquire Of (D) (Inst	d (A) or	5. Amoui Securitie Beneficia Owned F	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	orted nsaction(s) tr. 3 and 4)			(Instr. 4)
Common Stock 01/01				01/20	/2015		A		8,900(1) A	\$0	171	171,842		D			
Common Stock 01/01				01/20	/2015		F		2,453(2) D	\$12.1	6 169),389		D			
			Table II -								osed of, onvertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	oate,	4. Transa Code (8)				6. Date Exercisal Expiration Date (Month/Day/Year)		e of Securities		ties ng e Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Emp. Stock Option (Right to Buy)	\$12.16	01/01/2015			A		42,400 ⁽³⁾		01/01/20)16	01/01/2025	Common Stock	42,400	\$0	42,40	0	D	

Explanation of Responses:

- 1. Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 2. Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013.
- 3. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of attorney 01/05/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.